Cargando…
T48. ANTIPSYCHOTIC EFFICACY OF EVENAMIDE (NW-3509) IS DUE TO MODULATION OF GLUTAMATERGIC DYSREGULATION
BACKGROUND: Over 70% of schizophrenic patients discontinue treatment with first (F)- or second-generation antipsychotics (SGA) due to dissatisfaction with their therapeutic effects; median time to discontinuation ranges from 3–7 months (1). Switching to another antipsychotic, except clozapine, did n...
Autores principales: | Anand, Ravi, Forrest, Emma C, Hartman, Richard D, Graham, Stephen M, Faravelli, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5887659/ http://dx.doi.org/10.1093/schbul/sby016.324 |
Ejemplares similares
-
T36. THE ANTIPSYCHOTIC-LIKE PROPERTIES OF EVENAMIDE (NW-3509) REFLECT THE MODULATION OF GLUTAMATERGIC DYSREGULATION
por: Bortolato, Marco, et al.
Publicado: (2018) -
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia
por: Anand, Ravi, et al.
Publicado: (2023) -
Evenamide, as an add-on to antipsychotics, benefits patients with treatment resistant schizophrenia: 6-month interim results from the first 100 patients in an ongoing international randomized study
por: Anand, R., et al.
Publicado: (2023) -
Mintaimycins, a Group of Novel Peptide Metabolites from Micromonospora sp. C-3509
por: Hu, Xiaomin, et al.
Publicado: (2022) -
3509 Developing a Leadership Alumni Forum to foster a culture of leadership at Mount Sinai
por: Gabrilove, Janice Lynn, et al.
Publicado: (2019)